This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CT-P53
Previous Study | Return to List | Next Study

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05906992
Recruitment Status : Not yet recruiting
First Posted : June 18, 2023
Last Update Posted : June 18, 2023
Sponsor:
Information provided by (Responsible Party):
Celltrion

Brief Summary:
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.

Condition or disease Intervention/treatment Phase
Relapsing-remitting Multiple Sclerosis Biological: CT-P53 Biological: US-Ocrevus Biological: EU-Ocrevus Phase 3

Detailed Description:
CT-P53, containing the active ingredient ocrelizumab, is a humanized monoclonal antibody that is being developed as a proposed biosimilar medicinal product to Ocrevus. The purpose of this study is to demonstrate similar efficacy, PK, PD and safety of CT-P53 and Ocrevus in patients with Relpasing-remitting Multiple Screlosis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 512 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Estimated Study Start Date : December 2023
Estimated Primary Completion Date : February 2027
Estimated Study Completion Date : January 2029

Resource links provided by the National Library of Medicine

Drug Information available for: Ocrelizumab

Arm Intervention/treatment
Experimental: CT-P53
CT-P53(Ocrelizumab)
Biological: CT-P53
Intravenous(IV) infusion
Other Name: Ocrelizumab

Active Comparator: US-Ocrevus
US-licensed Ocrevus(Ocrelizumab)
Biological: US-Ocrevus
Intravenous(IV) infusion
Other Name: Ocrelizumab

Active Comparator: EU-Ocrevus
EU-approved Ocrevus(Ocrelizumab)
Biological: EU-Ocrevus
Intravenous(IV) infusion
Other Name: Ocrelizumab




Primary Outcome Measures :
  1. Area under the concentration-time curve in PK group [ Time Frame: Up to Week 24 ]

    To demonstrate PK comparability in terms of the area under the concentration time curve in patients with RRMS as follows:

    • Area under the concentration-time curve from time zero to Week 2 (AUC0-wk2)
    • Area under the concentration-time curve from Week 2 to Week 24 (AUCwk2-wk24)

  2. Total number of new GdE lesions on T1-weighted brain MRI in Main study group [ Time Frame: Up to Week 24 ]
    To demonstrate the equivalence of CT-P53 to reference drug (EU-Ocrevus and US-Ocrevus) in terms of efficacy in patients with RRMS as determined by the total number of new gadolinium-enhancing (GdE) lesions on T1-weighted brain magnetic resonance imaging (MRI)


Secondary Outcome Measures :
  1. Absoulte CD19+ B-cell counts for PD assessments [ Time Frame: Up to Week 96 ]

    To assess PD of CT-P53 and reference drug (EU-Ocrevus and US-Ocrevus) as follows:

    • Absolute CD19+ B-cell counts


  2. Area under the concentration-time curve in PK group [ Time Frame: Up to Week 16 ]
    Area under the concentration-time curve from time zero to Week 16

  3. Total body clearance in PK group [ Time Frame: Up to Week 2 ]
    Total body clearance covering both administrations at Weeks 0 and 2 (CL)

  4. Volume of distribution at steady state in PK group [ Time Frame: Up to Week 2 ]
    Volume of distribution at steady state covering both administrations at Week 0 and 2 (Vss)

  5. Safety: Immunogenecity [ Time Frame: Up to Week 96 ]
    Number and percentage of patients with positive antidrug-antibody and neutralizing antibody results

  6. Annualized Relapse Rate (ARR) [ Time Frame: Up to Week 96 ]
    The total number of protocol-defined MS relapses for each patient will be counted and listed. Annualized relapse rate (ARR) will be calculated by the total number of protocol-defined relapses for all patients divided by time-in-study by patient.

  7. Change in Expanded Disability Status Score (EDSS) [ Time Frame: Up to Week 96 ]

    The EDSS score will be listed and descriptive statistics for actual value and change in EDSS score from baseline to Weeks 24, 48 and 96 will be summarized by treatment group and visit.

    An increase ≥1.5 point from baseline EDSS score is defined as disability progression.

    A reduction ≥1.0 point from baseline EDSS score is defined as disability improvement.


  8. Change in Multiple Sclerosis Functional Composite Score (MSFCS) [ Time Frame: Up to Week 96 ]
    There are three components to the MSFCS; (1) the average scores of two trials of T25-FW (2) the average scores on the 9-HPT (the two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged) (3) the number of correct answers from the PASAT-3. Multiple Sclerosis Functional Composite Score (MSFCS) is based on the concept that scores for these three dimensions (arm, leg, and cognitive functions) are combined to create a single score (the MSFCS) that can be used to detect change over time in MS patients

  9. Total Number of Lesions on Brain Magnetic Resonance Imaging [ Time Frame: Up to Week 96 ]
    The total number of lesions on brain MRI will be calculated as the cumulative sum of the individual number of the lesions at each scheduled visit

  10. Volume of Hypointense Lesions on T1-weighted Brain Magnetic Resonance Imaging [ Time Frame: Up to Week 96 ]
    Actual value of volume of hypointense lesions on T1-weighted brain MRI will be listed by treatment group and visit. Descriptive statistics for actual value and change in volume of hypointense lesions on T1-weighted brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group

  11. Brain Volume on Brain Magnetic Resonance Imaging [ Time Frame: Up to Week 96 ]
    Change in brain volume is defined as the brain volume at pre-specified time point minus brain volume at baseline. Actual value of brain volume on brain MRI will be listed by treatment group. Descriptive statistics for actual value and percentage change in brain volume on brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group.

  12. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to Week 96 ]
    All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDonald criteria.
  • Patient has evidence of recent MS activity as defined in the study protocol
  • Patient has neurological stability for ≥30 days.
  • Patient with 0 to 6.0 (both inclusive) on the EDSS score.

Exclusion Criteria:

  • Patient diagnosed with primary or secondary progressive MS.
  • Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.
  • Patient unable to complete or has a contraindication to an MRI
  • Patient with contraindications and/or severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.
  • Patient who has currently or history of any of medical conditions described in the study protocol.
  • Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05906992


Contacts
Layout table for location contacts
Contact: SoYoung Yoo +82 32 850 5791 soyoung.yoo@celltrion.com
Contact: JinHo Lee +82 32 850 5787 jinho.lee2@celltrion.com

Sponsors and Collaborators
Celltrion
Investigators
Layout table for investigator information
Study Chair: Minji Ma Celltrion, Inc.
Layout table for additonal information
Responsible Party: Celltrion
ClinicalTrials.gov Identifier: NCT05906992    
Other Study ID Numbers: CT-P53 3.1
First Posted: June 18, 2023    Key Record Dates
Last Update Posted: June 18, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Ocrelizumab
Immunologic Factors
Physiological Effects of Drugs